Treatment of degenerative dementia disorders - who should be treated?;Behandling af demenssygdomme - hvem skal behandles?

Ugeskrift for Laeger

Volumn 171, Issue 10, 2009, Pages 802-805

  Hasselbalch, Steen G ^a   Kampmann, Jens Peter ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; MEMANTINE; NEUROPROTECTIVE AGENT; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DRUG COMBINATION; EVIDENCE BASED MEDICINE; HUMAN; MIDDLE AGED; PARKINSON DISEASE; PATIENT SELECTION;

AGED; ALZHEIMER DISEASE; ANTIPARKINSON AGENTS; CHOLINESTERASE INHIBITORS; DEMENTIA; DOPAMINE AGENTS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; LEWY BODY DISEASE; MEMANTINE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PATIENT SELECTION; PHENYLCARBAMATES;

EID: 62249168915     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Udredning og behandling af demens - en medicinsk teknologivurdering. København: Sundhedsstyrelsen, Monitorering & Medicinsk Teknologivurdering, 2008. Medicinsk Teknologivurdering 2008;10.
2. Statens beredning för medicinsk utvärdering. Dementia - diagnostic and therapeutic interventions. A systemativ review of the literature. Sverige: Statens beredning för medicinsk utvärdering, 2008.
3. Waldemar G, Dubois B, Emre M et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007;14:e1-e26.
4. Spijker A, Vernooij-Dassen M, Vasse E et al. Effectiveness of nonpharmacological interventions in delaying the institutionalization of patients with dementia: a meta-analysis. J Am Geriatr Soc 2008;56:1116-28.
5. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization, 1992.
6. Burns A, O'Brien J, Auriacombe S et al. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol 2006;20:732-55.
7. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: A meta-analysis of randomised controlled trials. Lancet Neurol 2007;6:749-51.
8. Stig Ejdrup Andersen. Specifikke lægemidler mod Alzheimers sygdom. www.irf.dk/dk/publikationer/rationel_farmakoterapi/maanedsblad/2007/specifikke_laegemidler_mod_alzheimers_sygdom.htm (15. august 2008).
9. Doody RS, Gavrilova SI, Sano M et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008;372:207-15.
10. Gura T. Hope in Alzheimer's fight emerges from unexpected places. Nat Med 2008;14:895.